Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AN OPEN-LABEL, RANDOMIZED, COMPARATIVE, MULTICENTRIC, PARALLEL GROUP, PHASE-III STUDY TO COMPARE THE EFFICACY AND SAFETY OF TWO SQUIRTS OF DICLOFENAC RECTAL SOLUTION WITH APPLICATOR (DICLOFENAC SODIUM 50 mg/squirt) OF LINCOLN PHARMACEUTICALS LTD, INDIA WITH JONAC SUPPOSITORY (DICLOFENAC SODIUM 100 mg) OF GERMAN REMEDIES (CADILA HEALTHCARE LTD.) IN PATIENTS WITH POST-OPERATIVE PAIN

Trial Profile

AN OPEN-LABEL, RANDOMIZED, COMPARATIVE, MULTICENTRIC, PARALLEL GROUP, PHASE-III STUDY TO COMPARE THE EFFICACY AND SAFETY OF TWO SQUIRTS OF DICLOFENAC RECTAL SOLUTION WITH APPLICATOR (DICLOFENAC SODIUM 50 mg/squirt) OF LINCOLN PHARMACEUTICALS LTD, INDIA WITH JONAC SUPPOSITORY (DICLOFENAC SODIUM 100 mg) OF GERMAN REMEDIES (CADILA HEALTHCARE LTD.) IN PATIENTS WITH POST-OPERATIVE PAIN

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jun 2018

At a glance

  • Drugs Diclofenac (Primary)
  • Indications Postoperative pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Lincoln Pharmaceuticals
  • Most Recent Events

    • 28 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top